Nutra Pharma (NPHC) Stock Price, News & Analysis

Company Overview

Nutra Pharma Corporation is a development-stage medical technology company focusing on the research and development of therapeutic products for gastrointestinal disorders, notably those arising from opioid use. The company is advancing a portfolio of proprietary formulations designed to address opioid-induced constipation (OIC), a common side effect of pain management regimens.

Its lead candidate, RIMSO-50, is an oral solution being evaluated for its potential to alleviate OIC by promoting bowel movements without compromising the effectiveness of opioid analgesics. Nutra Pharma is leveraging its in-house formulation capabilities and preclinical data to support ongoing regulatory submissions and potential partner collaborations.

Nutra Pharma holds patent protection in key jurisdictions, including the United States, Europe and Israel, covering its novel formulations and methods of use. The company’s intellectual property strategy is aimed at securing market exclusivity and facilitating potential licensing agreements.

Headquartered in Tel Aviv, Israel, Nutra Pharma is building its operational footprint with activities in North America and Europe. While the company remains in the clinical and regulatory phase, it seeks to advance its product pipeline through strategic partnerships and capital investment to bring its therapies to patients in need.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0050
• Volume: 9,000 shs
• Average Volume: 717,123 shs
• Market Capitalization: $715.97 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/17/2018
• Today: 8/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:NPHC
• CIK: 1119643
• Web: www.nutrapharma.com
• Phone: (954) 509-0911
• Fax: 877-895-5647
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.05 million
• Net Margins: -2,093.05%
• Pretax Margin: -2,093.05%
• Return on Equity: N/A
• Return on Assets: -317.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.02
• Quick Ratio: 0.02

Sales & Book Value

• Annual Sales: $380 thousand
• Price / Sales: 1.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,159,730,000
• Free Float: 2,756,495,000
• Market Cap: $715.97 thousand
• Optionable: Not Optionable
• Beta: 0.94